Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study

More than half of the patients with advanced hepatocellular carcinoma (HCC) do not respond to primary treatment with sorafenib. Currently, there are no universally accepted methods for further treatment. This pilot study was performed to assess the safety and effectiveness of apatinib as an optional...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yingqiang, Fan, Wenzhe, Wang, Yu, Huang, Guihua, Li, Jiaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719480/
https://www.ncbi.nlm.nih.gov/pubmed/31466465
http://dx.doi.org/10.1177/1073274819872216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719480/
https://www.ncbi.nlm.nih.gov/pubmed/31466465
http://dx.doi.org/10.1177/1073274819872216

Ejemplares similares